|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
3/2017
vol. 119 abstract:
Original paper
Anti-VEGF treatment of idiopathic, active choroidal neovascularization in patients below 45 years of age
Adam Cywiński
1
,
Anna Piwońska-Lobermajer
1
,
Małgorzata Świgoń
1
,
Marcin Gacek
1, 2
Online publish date: 2018/06/05
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
The aim of the current work is to discuss the “off label” anti-VEGF therapy in patients under 45 years of age with idiopathic choroidal neovascularization within the macular area in the context of retrospective analysis of four patients (6 eyes), whose treatment started at different stages of the disease. Visual acuity improvement was achieved in 3 patients (5 eyes). In the fourth patient, the treatment was discontinued after one injection due to the lack of improvement. The degree of the improvement depended on the time of treatment initiation, location and severity of macular abnormalities. Anti-VEGF drugs provide good outcomes in idiopathic choroidal neovascularization, although this is an “off label” treatment. Treatment commencement at early stages of the disease increases chances for achieving and maintaining good visual function.
keywords:
anti-VEGF therapy, idiopathic choroidal neowascular membrane |
|
POLSKI
